Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update

Manfred Kaufmann; Gabriel N. Hortobagyi; Ann Goldhirsch; Suzy Scholl; Andreas Makris; Pinuccia Valagussa; Jens Uwe Blohmer; Wolfgang Eiermann; Raimund Jackesz; Walter Jonat; Annette Lebeau; Sibylle Loibl; William Miller; Sigfried Seeber; Vladimir Semiglazov; Roy Smith; Rainer Souchon; Vered Stearns; Michael Untch; Gunter Von Minckwitz

doi:10.1200/JCO.2005.02.6187

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update

Manfred Kaufmann, Gabriel N. Hortobagyi, Ann Goldhirsch, Suzy Scholl, Andreas Makris, Pinuccia Valagussa, Jens Uwe Blohmer, Wolfgang Eiermann, Raimund Jackesz, Walter Jonat, Annette Lebeau, Sibylle Loibl, William Miller, Sigfried Seeber, Vladimir Semiglazov, Roy Smith, Rainer Souchon, Vered Stearns, Michael Untch, Gunter Von Minckwitz

Research output: Contribution to journal › Review article › peer-review

490 Scopus citations

Abstract

Neoadjuvant (primary systemic) treatment is the standard treatment for locally advanced breast cancer and a standard option for primary operable disease. Because of new treatments and new understandings of breast cancer, however, recommendations published in 2003 regarding neoadjuvant treatment for operable disease required updating. Therefore, a second international panel of representatives of a number of breast cancer clinical research groups was convened in September 2004 to update these recommendations. As part of this effort, data published to date were reviewed critically and indications for neoadjuvant treatment were newly defined.

Original language	English (US)
Pages (from-to)	1940-1949
Number of pages	10
Journal	Journal of Clinical Oncology
Volume	24
Issue number	12
DOIs	https://doi.org/10.1200/JCO.2005.02.6187
State	Published - Apr 20 2006
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1200/JCO.2005.02.6187

Cite this

Kaufmann, M., Hortobagyi, G. N., Goldhirsch, A., Scholl, S., Makris, A., Valagussa, P., Blohmer, J. U., Eiermann, W., Jackesz, R., Jonat, W., Lebeau, A., Loibl, S., Miller, W., Seeber, S., Semiglazov, V., Smith, R., Souchon, R., Stearns, V., Untch, M., & Von Minckwitz, G. (2006). Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update. Journal of Clinical Oncology, 24(12), 1940-1949. https://doi.org/10.1200/JCO.2005.02.6187

Kaufmann, M, Hortobagyi, GN, Goldhirsch, A, Scholl, S, Makris, A, Valagussa, P, Blohmer, JU, Eiermann, W, Jackesz, R, Jonat, W, Lebeau, A, Loibl, S, Miller, W, Seeber, S, Semiglazov, V, Smith, R, Souchon, R, Stearns, V, Untch, M & Von Minckwitz, G 2006, 'Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update', Journal of Clinical Oncology, vol. 24, no. 12, pp. 1940-1949. https://doi.org/10.1200/JCO.2005.02.6187

@article{9eb8bc9bc02a48d78b3f5c94572d2f31,

title = "Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update",

abstract = "Neoadjuvant (primary systemic) treatment is the standard treatment for locally advanced breast cancer and a standard option for primary operable disease. Because of new treatments and new understandings of breast cancer, however, recommendations published in 2003 regarding neoadjuvant treatment for operable disease required updating. Therefore, a second international panel of representatives of a number of breast cancer clinical research groups was convened in September 2004 to update these recommendations. As part of this effort, data published to date were reviewed critically and indications for neoadjuvant treatment were newly defined.",

author = "Manfred Kaufmann and Hortobagyi, {Gabriel N.} and Ann Goldhirsch and Suzy Scholl and Andreas Makris and Pinuccia Valagussa and Blohmer, {Jens Uwe} and Wolfgang Eiermann and Raimund Jackesz and Walter Jonat and Annette Lebeau and Sibylle Loibl and William Miller and Sigfried Seeber and Vladimir Semiglazov and Roy Smith and Rainer Souchon and Vered Stearns and Michael Untch and {Von Minckwitz}, Gunter",

year = "2006",

month = apr,

day = "20",

doi = "10.1200/JCO.2005.02.6187",

language = "English (US)",

volume = "24",

pages = "1940--1949",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "12",

}

TY - JOUR

T1 - Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer

T2 - An update

AU - Kaufmann, Manfred

AU - Hortobagyi, Gabriel N.

AU - Goldhirsch, Ann

AU - Scholl, Suzy

AU - Makris, Andreas

AU - Valagussa, Pinuccia

AU - Blohmer, Jens Uwe

AU - Eiermann, Wolfgang

AU - Jackesz, Raimund

AU - Jonat, Walter

AU - Lebeau, Annette

AU - Loibl, Sibylle

AU - Miller, William

AU - Seeber, Sigfried

AU - Semiglazov, Vladimir

AU - Smith, Roy

AU - Souchon, Rainer

AU - Stearns, Vered

AU - Untch, Michael

AU - Von Minckwitz, Gunter

PY - 2006/4/20

Y1 - 2006/4/20

N2 - Neoadjuvant (primary systemic) treatment is the standard treatment for locally advanced breast cancer and a standard option for primary operable disease. Because of new treatments and new understandings of breast cancer, however, recommendations published in 2003 regarding neoadjuvant treatment for operable disease required updating. Therefore, a second international panel of representatives of a number of breast cancer clinical research groups was convened in September 2004 to update these recommendations. As part of this effort, data published to date were reviewed critically and indications for neoadjuvant treatment were newly defined.

AB - Neoadjuvant (primary systemic) treatment is the standard treatment for locally advanced breast cancer and a standard option for primary operable disease. Because of new treatments and new understandings of breast cancer, however, recommendations published in 2003 regarding neoadjuvant treatment for operable disease required updating. Therefore, a second international panel of representatives of a number of breast cancer clinical research groups was convened in September 2004 to update these recommendations. As part of this effort, data published to date were reviewed critically and indications for neoadjuvant treatment were newly defined.

UR - http://www.scopus.com/inward/record.url?scp=33646375742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646375742&partnerID=8YFLogxK

U2 - 10.1200/JCO.2005.02.6187

DO - 10.1200/JCO.2005.02.6187

M3 - Review article

C2 - 16622270

AN - SCOPUS:33646375742

SN - 0732-183X

VL - 24

SP - 1940

EP - 1949

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 12

ER -

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this